论文部分内容阅读
近年研究提示,体外非侵袭起搏是终止室性和室上性心动过速的有效方法。为证明其在急诊科环境终止广泛复杂的心动过速的可能作用,以6例评价了该方法。材料与方法:6例(5男,1女)。中位年龄57(33～84)岁。到急诊科时有持续性广泛复杂的室性心动过速。5例用Amiodarone、心律平、喹尼丁,慢心律稳定血流动力学足够时间,以便起搏器(ZMI)安全附着病员。调整起搏器,使之跟踪体外刺激源至发生。刺激源(5320型)是暂时性心房起搏器发生器,能达到终止心动过速所需的任何频率。体外脉冲振幅稳定于120mA。起搏前每例静注Midazolam 1～3mg。以频率200次/min传递8～10次体外脉冲异步系
Recent studies suggest that noninvasive pacing in vitro is an effective method to terminate ventricular tachycardia and supraventricular tachycardia. To demonstrate its potential role in terminating a wide range of complex tachycardias in the ED setting, the method was evaluated in 6 patients. Materials and Methods: 6 cases (5 males and 1 female). The median age 57 (33 ~ 84) years old. Continued extensive complex ventricular tachycardia to the emergency department. Five patients had stable hemodynamics with Amiodarone, cardioversion, quinidine, and slow heartbeat for sufficient time to safely attach the pacemaker (ZMI) to the patient. Adjust the pacemaker so that it tracks the in vitro stimulation source until it occurs. The stimulus (Model 5320) is a temporary atrial pacemaker generator that reaches any frequency required to terminate tachycardia. In vitro pulse amplitude stabilized at 120mA. Each case of intravenous infusion of Midazolam 1 ~ 3mg before pacing. The frequency of 200 times / min delivery of 8 to 10 in vitro pulse asynchronous system